Document is current
Any future updates will be listed below
-
Authors
Zuniga, Richard
Dembla, Vikas
Alam, Naheed
Nangia, Chaitali
Guerrero-Garcia, Thomas
Chung, Gina
Kio, Ebenezer
Go, Mylene
Tubb, Erev
Sonis, Stephen https://orcid.org/0000-0001-6480-2625
Jacobucci, Frank
-
Funding
Funding for this research was provided by:
ChemoMouthpiece LLC
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 21 July 2025
First Online: 31 July 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and reviewed and approved by regional (WIRB-Copernicus Group IRB) or institutional IRBs.
: Preliminary results of portions of this trial were presented as an abstract at the 2024 Annual Meeting of MASCC held in Lille, France; Supportive Care in Cancer (2024) 32 (Suppl 1):S434.
: RZ is a consultant for Mirati Therapeutics, Flatiron and Bristol-Myers Squibb (BMS) and has received research and travel support from ChemoMouthpiece, LLC; VD participates in a Speaker Bureau for BMS/Regeneron and has equity in BMS; NA, GC, CN, EK, ET, MG, TG have no conflicts to declare; FJ is an employee of ChemoMouthpiece; SS is an employee of Biomodels, LLC and Primary Endpoint Solutions, LLC. Both companies assist industry (including ChemoMouthpiece), government and academics to study and enable drugs, biologicals, and devices to treat patients for a variety of indications including cancer and side effects and toxicities of its treatment.
